Cancer-related fatigue and associated disability in post-treatment cancer survivors
the ONA take:
Cancer-related fatigue (CRF) is the most common symptom for patients with cancer. However, data on its prevalence in the posttreatment period is limited.
Using a self-administered mail-based questionnaire, these researchers sought to measure occurrence of CRF in three cohorts (16 to 18 months posttreatment, 2 to 3 years posttreatment, and 5 to 6 years posttreatment) of disease-free survivors of breast, prostate, or colorectal cancer.
The study generated a 63% response rate (2,294 questionnaire packages were returned). Twenty-nine percent of respondents reported significant fatigue, although fatigue levels did not differ between time cohorts.
Reports of fatigue were significantly higher in survivors of breast or colorectal cancer compared with survivors of prostate cancer.
The researchers conclude that approximately one-third of cancer survivors experience fatigue for up to 6 years after treatment. Clinicians should be aware that fatigue can be a chronic condition, and should routinely assess for it.
Cancer-related fatigue is the most common symptom for patients with cancer.
- Physical Activity Improves Outcomes for Patients with Breast Cancer and Survivors
- Behavior Pain Assessment Tool Measures Pain In Patients Who Cannot Communicate Verbally
- Whole Genome Sequencing Reveals that 12% of Childhood Cancer Survivors Have Mutations in Genes that Increase Cancer Risk
- Novel Test For Multiple Myeloma Uses Microchip, Conventional Blood Sample
- Increased 5-Year Survival Rate Seen in NSCLC Subset Treated With Nivolumab
- Exercise, Psychological Interventions Better for Cancer Fatigue Than Medications
- ASCO Issues Global Guidance for HPV Vaccination for Cervical Cancer Prevention
- Discharge Events Improved With Standardized Inpatient Palliative Care Consultation
- Little Opposition to Early Palliative Care for Symptom Management in Pediatric Oncology
- Updated ASTRO Guideline Bolsters Safety, Efficacy of Palliative RT for Bone Metastases
- Thyroid Cancer Incidence Increasing Among Younger, Hispanic, African American Populations
- JAK1, JAK2 Inhibition Improves Outcomes in Myeloproliferative Neoplasms, But More Is Needed
- Recommendations Against Contralateral Prophylactic Mastectomy Not Tied to Patient Satisfaction
- Self-efficacy Level Predictive of Likelihood to Follow Through With Colorectal Cancer Screening
- Chronic Myeloproliferative Neoplasms Treatment (Fact Sheet)
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|